Omalizumab therapy for bullous pemphigoid

Kenneth K Yu; Ashley B Crew; Kelly A.N Messingham; Janet A Fairley; David T Woodley

doi:10.1016/j.jaad.2014.04.053

Back

Omalizumab therapy for bullous pemphigoid

Journal article

Open access

Omalizumab therapy for bullous pemphigoid

Kenneth K Yu, Ashley B Crew, Kelly A.N Messingham, Janet A Fairley and David T Woodley

Journal of the American Academy of Dermatology, Vol.71(3), pp.468-474

09/2014

DOI: 10.1016/j.jaad.2014.04.053

PMID: 24954907

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/9215508View

Open Access

Abstract

Bullous pemphigoid (BP) responds to a variety of immunosuppressive agents and usually controls, but does not cure, the disease. Omalizumab, Food and Drug Administration–approved for asthma, selectively suppresses the activity of IgE, an important immunoglobulin in the pathogenesis of BP. We wished to determine if systemic omalizumab would have a therapeutic effect in patients with BP. We treated 6 patients with BP using omalizumab and followed up their disease for up to 42 months. Although variable, 5 of the 6 patients with BP received therapeutic benefit from systemic omalizumab (the sixth terminated treatment because of intercurrent illness) with less use of other immunosuppressants, inhibition of new bullae, less pruritus, and dramatic decreases in eosinophil counts. None of the patients had untoward side effects from omalizumab. This was an open, uncontrolled study. Omalizumab neutralizes the activity of IgE in patients with BP and improves the control of their disease activity.

pruritus

bullous pemphigoid

omalizumab

autoimmunity

IgE

Details

Title: Subtitle: Omalizumab therapy for bullous pemphigoid
Creators: Kenneth K Yu - Keck School of Medicine, University of Southern California, Los Angeles, California
Ashley B Crew - Keck School of Medicine, University of Southern California, Los Angeles, California
Kelly A.N Messingham - Carver College of Medicine, University of Iowa, Iowa City, Iowa
Janet A Fairley - Carver College of Medicine, University of Iowa, Iowa City, Iowa
David T Woodley - Keck School of Medicine, University of Southern California, Los Angeles, California
Resource Type: Journal article
Publication Details: Journal of the American Academy of Dermatology, Vol.71(3), pp.468-474
DOI: 10.1016/j.jaad.2014.04.053
PMID: 24954907
NLM abbreviation: J Am Acad Dermatol
ISSN: 0190-9622
eISSN: 1097-6787
Publisher: Elsevier Inc
Language: English
Date published: 09/2014
Academic Unit: Dermatology
Record Identifier: 9984025417002771

Metrics

24 Record Views

127 Times Cited - Web of Science

See more details